Scribe Therapeutics Silences Heart Disease Gene Without Cutting DNA

Cardiovascular disease kills more people globally than any other condition, and much of that damage accumulates silently over decades through elevated LDL cholesterol. A new approach from biotech company Scribe Therapeutics aims to address this at the genetic level — not by rewriting DNA permanently, but by quieting the genes that drive the problem in the first place.

Presented at the 2026 American Society of Gene and Cell Therapy Annual Meeting, Scribe's ELXR platform is an epigenetic silencer targeting PCSK9, a gene that regulates LDL cholesterol. People born with naturally low PCSK9 activity have significantly lower lifetime rates of heart disease. Rather than cutting the gene out using traditional CRISPR scissors, ELXR dampens its activity — comparable to lowering a volume dial rather than destroying the speaker entirely.

The preclinical results are notable on two fronts. First, in non-human primates, a single treatment produced sustained cholesterol-related effects lasting nearly 18 months, with the study still ongoing. Second, the platform incorporates a dual-recognition safety mechanism — described as molecular two-factor authentication — that reduced unintended off-target genetic activity by 10 to 100 times compared to earlier systems, while improving on-target silencing.

For longevity medicine, the implications are significant. Chronic daily medications carry adherence challenges, side effects, and cumulative costs. A therapy that durably reduces lifetime cholesterol exposure after infrequent dosing could meaningfully lower cardiovascular risk across decades — the kind of upstream intervention that aging researchers consistently identify as high-leverage.

Important caveats apply. All data are preclinical, meaning results come from animal models and cell studies, not human trials. Translating gene-editing therapies into safe, approved human treatments remains scientifically and regulatorily complex. Epigenetic silencing is also a newer modality with less long-term safety data than conventional drugs. Nonetheless, the directional progress — greater precision, longer duration, fewer off-target effects — moves CRISPR meaningfully closer to preventive cardiovascular medicine.